Suwanee, GA, United States
Suwanee, GA, United States

Time filter

Source Type

News Article | December 21, 2016
Site: www.prnewswire.co.uk

According to a new market research report "Nuclear Imaging Equipment Market by Product (SPECT (Hybrid SPECT, Standalone SPECT), Hybrid PET, & Planar Scintigraphy), Application (Oncology, Cardiology & Neurology) & End user (Hospitals, Imaging Centers) - Global Forecasts to 2021", published by MarketsandMarkets, this report studies the global market for the forecast period of 2016 to 2021. This market is expected to reach USD 2.85 Billion by 2021 from USD 2.25 Billion in 2016, growing at a CAGR of 4.8%. Browse 84 market data Tables and 43 Figures spread through 166 Pages and in-depth TOC on "Nuclear Imaging Equipment Market" Early buyers will receive 10% customization on this report. The global Nuclear Imaging Equipment Market is segmented on the basis of product, application, end user, and region. Based on product, the Nuclear Imaging Equipment Market is categorized into SPECT systems, hybrid PET systems, and planar scintigraphy. In 2016, the SPECT systems segment is expected to account for the largest share of the Nuclear Imaging Equipment Market. The SPECT systems are further segmented into hybrid SPECT and standalone SPECT systems. In 2016, the hybrid SPECT segment is expected to account for the largest share of the SPECT Nuclear Imaging Equipment Market. Advantages such as better imaging ability, high resolution, and the ability to show molecular processes in vivo render hybrid SPECT systems superior than standalone systems. Based on application, the Nuclear Imaging Equipment Market is segmented into oncology, cardiology, neurology, and other applications (orthopedics, urology, thyroid-related disorders, and gastroenterology). In 2016, the oncology application segment is expected to account for the largest share of the nuclear imaging equipment applications market. The rising incidence and prevalence of cancer across the globe, initiatives taken by public and private organizations to curb the same, and development of advanced systems and radiotracers for oncology are the key factors contributing to the large share of the oncology segment. Based on end user, the nuclear imaging market is segmented into hospitals, imaging centers, academic & research centers, and other end users (pharmaceutical & biotechnology companies and CROs). In 2016, the hospitals segment is expected to account for the largest share of the market. The rise in the use of advanced imaging solutions and hybrid imaging systems in hospitals and enhanced care quality is driving the growth of this segment. Based on region, the Nuclear Imaging Equipment Market is divided into North America, Europe, Asia-Pacific, and Rest of the World (RoW). The RoW region comprises Latin America, the Middle East and Africa. In 2016, North America is projected to account for the largest share of the Nuclear Imaging Equipment Market, followed by Asia-Pacific and Europe. Increase in adoption of nuclear imaging technologies and rapid growth in aging population, along with high incidence and prevalence of chronic diseases, are propelling the growth of the North American Nuclear Imaging Equipment Market. Factors driving the global market include introduction of new and advanced products, investment for the modernization of diagnostic imaging centers, development of new radiotracers, and increasing incidence and prevalence of cancer & cardiovascular diseases. However, factors such as shutdown of National Research Universal (NRU) reactor, high cost of nuclear imaging equipment, and shorter half-life of radiopharmaceuticals are hindering the growth of the market. The major players in the global Nuclear Imaging Equipment Market are Siemens Healthineers (Germany), Philips Healthcare (Netherlands), and GE Healthcare (U.S.). These companies are dominant in the nuclear imaging market mainly due to their well-established presence in the field of medical imaging, presence in over 50 countries, high R&D investments, and strong sales and distribution force. The other players in the market include Toshiba Medical Systems Corporation (Japan), Neusoft Medical Systems Co., Ltd. (China), Mediso Medical Imaging Systems Ltd. (Hungary), Digirad Corporation (U.S.), CMR Naviscan Corporation (U.S.), SurgicEye GmbH (Germany), and DDD Diagnostics (Denmark). NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET by Type (Diagnostic (SPECT - Technetium, PET - F-18), Therapeutic (Beta Emitters - I-131, Alpha Emitters, Brachytherapy - Y-90) & by Application (Oncology, Thyroid, Cardiology) - Global Forecasts to 2021. MarketsandMarkets is the largest market research firm worldwide in terms of annually published premium market research reports. Serving 1700 global fortune enterprises with more than 1200 premium studies in a year, M&M is catering to a multitude of clients across 8 different industrial verticals. We specialize in consulting assignments and business research across high growth markets, cutting edge technologies and newer applications. Our 850 fulltime analyst and SMEs at MarketsandMarkets are tracking global high growth markets following the "Growth Engagement Model - GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors. M&M's flagship competitive intelligence and market research platform, "RT" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets. The new included chapters on Methodology and Benchmarking presented with high quality analytical infographics in our reports gives complete visibility of how the numbers have been arrived and defend the accuracy of the numbers. We at MarketsandMarkets are inspired to help our clients grow by providing apt business insight with our huge market intelligence repository. Connect with us on LinkedIn @ http://www.linkedin.com/company/marketsandmarkets


SUWANEE, Ga., Feb. 24, 2017 (GLOBE NEWSWIRE) -- Digirad Corporation (Nasdaq:DRAD) today reported its financial results for the fourth quarter and twelve months ended December 31, 2016. Total revenues for the fourth quarter were $31.1 million, an increase of 100 percent compared to the prior year’s fourth quarter revenues of $15.6 million. Net income for the fourth quarter was $2.0 million, or $0.10 diluted earnings per share (EPS), compared to net income of $0.7 million, or $0.03 diluted EPS from the same period in the prior year.  Non-GAAP adjusted net income for the fourth quarter was $3.0 million, or $0.15 diluted EPS, compared to $1.3 million, or $0.07 diluted EPS from the same period in the prior year. Non-GAAP adjusted EBITDA for the fourth quarter was $5.4 million, compared to $2.1 million in the same period in the prior year. Total revenues for the twelve months ended December 31, 2016 were $125.5 million, an increase of 106 percent compared to the prior year’s revenues of $60.8 million. Net income for the twelve months ended December 31, 2016 was $14.3 million, or $0.71 diluted EPS, compared to net income of $21.6 million, or $1.10 diluted EPS in the same period in the prior year.  Non-GAAP adjusted net income for the twelve months ended December 31, 2016 was $7.2 million, or $0.36 diluted EPS, compared to non-GAAP adjusted net income of $4.5 million, or $0.23 diluted EPS in the same period in the prior year. Non-GAAP adjusted EBITDA for the twelve months ended December 31, 2016 was $16.8 million, compared to $7.2 million in the same period in the prior year. A reconciliation of non-GAAP adjusted net income and non-GAAP adjusted EBITDA is provided later in this release. The results for the fourth quarter and twelve months ended December 31, 2016 include the results of the recent acquisition of DMS Health, which closed on January 1, 2016. Digirad President and CEO Matt Molchan said, “We are very pleased with our results for the quarter, where we experienced exceptional product sales performance, as well as great performance from our service businesses, capping off a transformational year for Digirad.” Molchan continued, “I am also pleased to report we have completed all of our operational integration activities related to the DMS Health acquisition, and will now be focusing our efforts on leveraging our combined resources as we move forward. Additionally, since entering our credit facility at the beginning of the year, we have paid down $11.7 million of the initial balance, including three extra principal payments. We continue to generate significant cash flow to maintain our stable dividend, fund organic growth and pursue accretive acquisitions.” The Company previously announced a cash dividend of $0.05 cents per share that will be paid on February 28, 2017, to shareholders of record on February 15, 2017. A conference call is scheduled for 10:00 a.m. EST on February 24, 2017 to discuss the results and management's outlook. The call may be accessed by dialing 1-877-407-9039 (international callers: +1-201-689-8470) five minutes prior to the scheduled start time and referencing Digirad. A simultaneous webcast of the call may be accessed online from the Events & Presentations link on the Investor Relations page at http://drad.client.shareholder.com; an archived replay of the webcast will be available within 15 minutes of the end of the conference call. Use of Non-GAAP Financial Measures by Digirad Corporation This Digirad news release presents the non-GAAP financial measures “adjusted net income,” “adjusted net income per diluted share,” and “adjusted EBITDA.” The most directly comparable measure for these non-GAAP financial measures are net income and diluted net income per share. The Company has included below unaudited adjusted financial information, which presents the Company's results of operations after excluding acquired intangible asset amortization, goodwill impairment, acquisition related contingent consideration adjustments, investment impairment loss, transaction and integration costs associated with DMS Health Technologies, and non-recurring related income tax adjustments.  Further excluded in the measure of adjusted EBITDA are interest, taxes, depreciation, amortization and stock-based compensation. A discussion of the reasons why management believes that the presentation of non-GAAP financial measures provides useful information to investors regarding Digirad's financial condition and results of operations is included as Exhibit 99.2 to Digirad's report on Form 8-K filed with the Securities and Exchange Commission on February 24, 2017. Digirad delivers convenient, effective, and efficient healthcare solutions on an as needed, when needed, and where needed basis.  Digirad’s diverse portfolio of mobile healthcare solutions and medical equipment and services, including diagnostic imaging and patient monitoring, provides hospitals, physician practices, and imaging centers through the United States access to technology and services necessary to provide exceptional patient care in the rapidly changing healthcare environment.  For more information, please visit www.digirad.com. This press release contains statements that are forward-looking statements as defined within the Private Securities Litigation Reform Act of 1995. Some of these forward-looking statements can be identified by the use of forward-looking words such as “believes,” “expects,” “may,” “will,” “should,” “seek,” “approximately,” “intends,” “plans,” “estimates,” or “anticipates,” or the negative of those words or other comparable terminology, or in specific statements such as the Company's ability to deliver value to customers, the ability to grow and generate positive cash flow, the ability to execute on restructuring activities, and ability to successfully execute acquisitions. These forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from the statements made. These risks are detailed in Digirad's filings with the U.S. Securities and Exchange Commission, including the Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and other reports. Readers are cautioned to not place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, and Digirad undertakes no obligation to revise or update the forward-looking statements contained herein.


News Article | October 31, 2016
Site: www.newsmaker.com.au

This report studies Nuclear Medicine Equipment in Global market, especially in North America, Europe, China, Japan, Southeast Asia and India, focuses on top manufacturers in global market, with production, price, revenue and market share for each manufacturer, covering  Philips Healthcare  GE Healthcare  Siemens Healthcare  Digirad Corporation  Mediso Medical Imaging Systems  Toshiba Medical Systems  DDD-Diagnostics A/S  Neusoft Medical Systems  SurgicEye  CMR Naviscan Market Segment by Regions, this report splits Global into several key Regions, with production, consumption, revenue, market share and growth rate of Nuclear Medicine Equipment in these regions, from 2011 to 2021 (forecast), like  North America  Europe  China  Japan  Southeast Asia  India Split by product type, with production, revenue, price, market share and growth rate of each type, can be divided into  hybrid PET  hybrid SPECT  standalone SPECT  planar scintigraphy systems Split by application, this report focuses on consumption, market share and growth rate of Nuclear Medicine Equipment in each application, can be divided into  Cardiology  Oncology  Neurology  Others Global Nuclear Medicine Equipment Market Research Report 2016  1 Nuclear Medicine Equipment Market Overview  1.1 Product Overview and Scope of Nuclear Medicine Equipment  1.2 Nuclear Medicine Equipment Segment by Type  1.2.1 Global Production Market Share of Nuclear Medicine Equipment by Type in 2015  1.2.2 hybrid PET  1.2.3 hybrid SPECT  1.2.4 standalone SPECT  1.2.5 planar scintigraphy systems  1.3 Nuclear Medicine Equipment Segment by Application  1.3.1 Nuclear Medicine Equipment Consumption Market Share by Application in 2015  1.3.2 Cardiology  1.3.3 Oncology  1.3.4 Neurology  1.3.5 Others  1.4 Nuclear Medicine Equipment Market by Region  1.4.1 North America Status and Prospect (2011-2021)  1.4.2 Europe Status and Prospect (2011-2021)  1.4.3 China Status and Prospect (2011-2021)  1.4.4 Japan Status and Prospect (2011-2021)  1.4.5 Southeast Asia Status and Prospect (2011-2021)  1.4.6 India Status and Prospect (2011-2021)  1.5 Global Market Size (Value) of Nuclear Medicine Equipment (2011-2021) 7 Global Nuclear Medicine Equipment Manufacturers Profiles/Analysis  7.1 Philips Healthcare  7.1.1 Company Basic Information, Manufacturing Base and Its Competitors  7.1.2 Nuclear Medicine Equipment Product Type, Application and Specification  7.1.2.1 Type I  7.1.2.2 Type II  7.1.3 Philips Healthcare Nuclear Medicine Equipment Production, Revenue, Price and Gross Margin (2015 and 2016)  7.1.4 Main Business/Business Overview  7.2 GE Healthcare  7.2.1 Company Basic Information, Manufacturing Base and Its Competitors  7.2.2 Nuclear Medicine Equipment Product Type, Application and Specification  7.2.2.1 Type I  7.2.2.2 Type II  7.2.3 GE Healthcare Nuclear Medicine Equipment Production, Revenue, Price and Gross Margin (2015 and 2016)  7.2.4 Main Business/Business Overview  7.3 Siemens Healthcare  7.3.1 Company Basic Information, Manufacturing Base and Its Competitors  7.3.2 Nuclear Medicine Equipment Product Type, Application and Specification  7.3.2.1 Type I  7.3.2.2 Type II  7.3.3 Siemens Healthcare Nuclear Medicine Equipment Production, Revenue, Price and Gross Margin (2015 and 2016)  7.3.4 Main Business/Business Overview  7.4 Digirad Corporation  7.4.1 Company Basic Information, Manufacturing Base and Its Competitors  7.4.2 Nuclear Medicine Equipment Product Type, Application and Specification  7.4.2.1 Type I  7.4.2.2 Type II  7.4.3 Digirad Corporation Nuclear Medicine Equipment Production, Revenue, Price and Gross Margin (2015 and 2016)  7.4.4 Main Business/Business Overview  7.5 Mediso Medical Imaging Systems  7.5.1 Company Basic Information, Manufacturing Base and Its Competitors  7.5.2 Nuclear Medicine Equipment Product Type, Application and Specification  7.5.2.1 Type I  7.5.2.2 Type II  7.5.3 Mediso Medical Imaging Systems Nuclear Medicine Equipment Production, Revenue, Price and Gross Margin (2015 and 2016)  7.5.4 Main Business/Business Overview  7.6 Toshiba Medical Systems  7.6.1 Company Basic Information, Manufacturing Base and Its Competitors  7.6.2 Nuclear Medicine Equipment Product Type, Application and Specification  7.6.2.1 Type I  7.6.2.2 Type II  7.6.3 Toshiba Medical Systems Nuclear Medicine Equipment Production, Revenue, Price and Gross Margin (2015 and 2016)  7.6.4 Main Business/Business Overview  7.7 DDD-Diagnostics A/S  7.7.1 Company Basic Information, Manufacturing Base and Its Competitors  7.7.2 Nuclear Medicine Equipment Product Type, Application and Specification  7.7.2.1 Type I  7.7.2.2 Type II  7.7.3 DDD-Diagnostics A/S Nuclear Medicine Equipment Production, Revenue, Price and Gross Margin (2015 and 2016)  7.7.4 Main Business/Business Overview  7.8 Neusoft Medical Systems  7.8.1 Company Basic Information, Manufacturing Base and Its Competitors  7.8.2 Nuclear Medicine Equipment Product Type, Application and Specification  7.8.2.1 Type I  7.8.2.2 Type II  7.8.3 Neusoft Medical Systems Nuclear Medicine Equipment Production, Revenue, Price and Gross Margin (2015 and 2016)  7.8.4 Main Business/Business Overview  7.9 SurgicEye  7.9.1 Company Basic Information, Manufacturing Base and Its Competitors  7.9.2 Nuclear Medicine Equipment Product Type, Application and Specification  7.9.2.1 Type I  7.9.2.2 Type II  7.9.3 SurgicEye Nuclear Medicine Equipment Production, Revenue, Price and Gross Margin (2015 and 2016)  7.9.4 Main Business/Business Overview  7.10 CMR Naviscan  7.10.1 Company Basic Information, Manufacturing Base and Its Competitors  7.10.2 Nuclear Medicine Equipment Product Type, Application and Specification  7.10.2.1 Type I  7.10.2.2 Type II  7.10.3 CMR Naviscan Nuclear Medicine Equipment Production, Revenue, Price and Gross Margin (2015 and 2016)  7.10.4 Main Business/Business Overview


Magnetic attachment for a multisided buttable module.


Two different collimation geometries are interleaved. Each collimation geometry samples a transaxial slice through the object being imaged. The even slices are of the same fan-beam geometry as the central head, but the odd slices are of different collimation geometry. Each slice covers an axial range that is the same as the pixel size of the solid-state detector, and aligns with the corresponding pixels in the axial direction.


First and second gamma radiation detector heads are oriented to image an area of a subject. The area of said subject is completely within a field of view that is defined between the first and second gamma radiation heads. Focal points of each of the first and second gamma radiation heads are also within an area defined between the first and second gamma radiation heads. A computer is programmed to receive image information from both the first gamma radiation detector head and the second gamma radiation detector head, and operating to use information from both the first gamma radiation detector head and the second gamma radiation detector head, as well as to use information indicative of a distance between the first gamma radiation detector head and the second gamma radiation detector head, to determine a location of an item of interest in the subject and between the first gamma radiation detector head and the second gamma radiation detector head, by calculating using information about similar triangles formed from known positions of the first gamma radiation detector head and the second gamma radiation detector head, and the information.


Patent
Digirad | Date: 2010-04-20

A SPECT system which scans over multiple separate scans and individually motion compensates the information obtained from each of these scans. The separate scans may be over different angular extents and may be for different purposes. One of the scans for example may be a scout scan, and the other scans may then be scans which concentrate on areas identified during the scout scan. Alternatively, the scans may all being exactly the same and stitched together after the individual motion compensation. Since each of the scans are shorter, the patient will presumably have moved less during each individual scan, and the amount of motion is hence presumably less.


News Article | February 28, 2017
Site: globenewswire.com

SUWANEE, Ga., Feb. 28, 2017 (GLOBE NEWSWIRE) -- Digirad Corporation (NASDAQ:DRAD), today announced that it will present at the 29th Annual ROTH Conference.  The event will feature close to 500 public and private growth companies and will take place March 12 – 15, 2017 at The Ritz-Carlton Laguna Niguel in Dana Point, CA. Matt Molchan, Digirad's President and CEO will provide an overview of the Company's business during a live presentation on Tuesday, March 14, at 4:00 p.m. PT / 7:00 p.m. ET.  Mr. Molchan and Mr. Jeff Keyes, Digirad’s CFO, will be available for meetings at the conference on March 14.  Portfolio managers and analysts who wish to request a meeting with management should contact their ROTH representative. A live webcast of the presentation will be available from the Events & Presentations link on the Investor Relations page of the Digirad website at www.digirad.com. Digirad delivers convenient, effective, and efficient healthcare solutions on an as needed, when needed, and where needed basis.  Digirad’s diverse portfolio of mobile healthcare solutions and medical equipment and services, including diagnostic imaging and patient monitoring, provides hospitals, physician practices, and imaging centers throughout the United States access to technology and services necessary to provide exceptional patient care in the rapidly changing healthcare environment.  For more information, please visit www.digirad.com.


SUWANEE, Ga., Feb. 15, 2017 (GLOBE NEWSWIRE) -- Digirad Corporation (NASDAQ:DRAD) will release financial results for its fourth quarter and year ended December 31, 2016, before the market opens on Friday, February 24, 2017. A conference call is scheduled for 10:00 a.m. EST (7:00 a.m. PST) on February 24, 2017 to discuss the results and management’s outlook.  The call may be accessed by dialing 1-877-407-9039 (international callers +1-201-689-8470).  A simultaneous webcast of the call may be accessed online from the Events & Presentations link on the Investor Relations page of the Digirad website at http://drad.client.shareholder.com; an archived replay of the webcast will be available within 15 minutes of the end of the conference call. Digirad delivers convenient, effective, and efficient healthcare solutions on an as needed, when needed, and where needed basis.  Digirad’s diverse portfolio of mobile healthcare solutions and medical equipment and services, including diagnostic imaging and patient monitoring, provides hospitals, physician practices, and imaging centers throughout the United States access to technology and services necessary to provide exceptional patient care in the rapidly changing healthcare environment.  For more information, please visit www.digirad.com.


News Article | November 18, 2016
Site: globenewswire.com

SUWANEE, Ga., Nov. 18, 2016 (GLOBE NEWSWIRE) -- Digirad Corporation (NASDAQ:DRAD), the leader in delivering convenient, effective, and efficient healthcare solutions on an as needed, when needed, and where needed basis, today announced that it will be presenting at the 9th annual LD Micro Main Event. The LD Micro Main Event is the largest independent conference for small/microcap companies and will take place December 6-8 at the Luxe Sunset Boulevard Hotel in Los Angeles, featuring over 200 presenting companies. Digirad President and CEO, Matt Molchan will provide an overview of the Company's business during a live presentation on Thursday, December 8, at 10:30 AM PST / 1:30 PM EST. Mr. Molchan, along with Digirad CFO, Jeff Keyes will be available for meetings at the conference on December 7, 2016. A live webcast of the presentation will be available from the Events & Presentations link on the Investor Relations page of the Digirad website at www.digirad.com or by following the link below: About Digirad Digirad delivers convenient, effective, and efficient healthcare solutions on an as needed, when needed, and where needed basis. Digirad’s diverse portfolio of mobile healthcare solutions and medical equipment and services, including diagnostic imaging and patient monitoring, provides hospitals, physician practices, and imaging centers throughout the United States access to technology and services necessary to provide exceptional patient care in the rapidly changing healthcare environment. For more information, please visit www.digirad.com. LD Micro was founded in 2006 with the sole purpose of being an independent resource in the microcap space. What started out as a newsletter highlighting unique companies has transformed into an event platform hosting several influential conferences annually (Invitational, Summit, and Main Event). In 2015, LD Micro launched the first pure microcap index (the LDMi) to exclusively provide intraday information on the entire sector. LD Micro will continue to provide valuable tools for the benefit of everyone in the small and microcap universe. For those interested in attending, please contact David Scher at david@ldmicro.com or visit www.ldmicro.com/events for more information.

Loading Digirad collaborators
Loading Digirad collaborators